These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25222341)

  • 1. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
    Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
    Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
    Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
    J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
    Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
    Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
    Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
    Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac and proinflammatory markers predict prognosis in cirrhosis.
    Wiese S; Mortensen C; Gøtze JP; Christensen E; Andersen O; Bendtsen F; Møller S
    Liver Int; 2014 Jul; 34(6):e19-30. PubMed ID: 24313898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation.
    Erbel R; Möhlenkamp S; Lehmann N; Schmermund A; Moebus S; Stang A; Grönemeyer D; Seibel R; Mann K; Volbracht L; Dragano N; Siegrist J; Jöckel KH;
    Atherosclerosis; 2008 Apr; 197(2):662-72. PubMed ID: 17386928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble urokinase plasminogen activator receptor is associated with cardiovascular calcification in peritoneal dialysis patients.
    Guan J; Gong S; He Q; Wang X; Shen S; Wu X; Shan J; Gong T; Yang Y; Xie H
    Int Urol Nephrol; 2024 Jan; 56(1):191-198. PubMed ID: 37195572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
    Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S
    Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.
    Haugaard SB; Andersen O; Hansen TW; Eugen-Olsen J; Linneberg A; Madsbad S; Olsen MH; Jørgensen T; Borch-Johnsen K; Jeppesen J
    Diabet Med; 2012 Apr; 29(4):479-87. PubMed ID: 22050462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between high-sensitive troponin I and coronary artery calcification in a Danish general population.
    Olson F; Engborg J; Grønhøj MH; Sand NP; Lambrechtsen J; Steffensen FH; Nybo M; Gerke O; Mickley H; Diederichsen AC
    Atherosclerosis; 2016 Feb; 245():88-93. PubMed ID: 26714045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
    Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
    Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.
    Toldi G; Szalay B; Bekő G; Bocskai M; Deák M; Kovács L; Vásárhelyi B; Balog A
    Biomarkers; 2012 Dec; 17(8):758-63. PubMed ID: 23033975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
    Borné Y; Persson M; Melander O; Smith JG; Engström G
    Eur J Heart Fail; 2014 Apr; 16(4):377-83. PubMed ID: 24464777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission.
    Toldi G; Bekő G; Kádár G; Mácsai E; Kovács L; Vásárhelyi B; Balog A
    Clin Chem Lab Med; 2013 Feb; 51(2):327-32. PubMed ID: 22718576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.